Clinical Trial Search

Phase 3 N=172 Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI

Acute Respiratory Infection

Primary: Fever Duration (With a Superiority Cut-off Level δ=-0,52 Days) — 2.04; 2.26 day — p=<0.05

NPO Petrovax Results Jun 2020 0.0% serious AE View details

Phase 3 N=500 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Early Breast Cancer

Primary: Trough Serum Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8) — 72.4; 88.7 micrograms per millilitre (μg/mL)

Hoffmann-La Roche Results Jun 2020 20.2% serious AE View details

Phase 3 N=459 A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

Chronic Idiopathic Constipation

Primary: Complete Spontaneous Bowel Movement (CSBM) Response — 47; 56 Participants — p=0.016

Braintree Laboratories Results Jun 2020 0.7% serious AE View details

Phase 3 N=658 Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

Ankle Sprain

Primary: Visual Analogue Scale (VAS) Scores at Baseline and Post Treatment — 68.56; 69.03; 25.34; 25.78 score on a scale

Actavis Inc. Results Jun 2020 0.0% serious AE View details

Phase 3 N=95 A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Attention-Deficit Hyperactivity Disorder (ADHD)

Primary: Change From Baseline at Day 15 in , ADHD Symptoms as Measured by Mean Swanson,Kotkin,Agler,M-Flynn, Pelham Rating Scale(SKAMP)-Combined Score Obtained From an Average of…

Sumitomo Pharma America, Inc. Results Jun 2020 0.0% serious AE View details

Phase 3 N=42 Efficacy of Amoxicillin-metronidazole Compared to Clindamycin in Patients With Periodontitis and Diabetes

Periodontitis · Periodontal Pocket · Diabetes Mellitus

Primary: Probing Depth — 0.44; 0.50 mm — p=<0.05

Centro Universitario de Tonalá Results Jun 2020 0.0% serious AE View details

Phase 3 N=1,001 Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

Acne

Primary: Percent Change From Baseline to Week 12 in the Number of Inflamed Lesions. — -74.2; -73.0; -30.6 percentage of change from baseline

Actavis Inc. Results Jun 2020 0.2% serious AE View details

Phase 3 N=9,350 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia · Adult B Lymphoblastic Lymphoma · Ann Arbor Stage I B Lymphoblastic Lymphoma

Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability

Children's Oncology Group Results Jun 2020 0.8% serious AE View details

Phase 3 N=2,639 European Celecoxib Trial in Primary Breast Cancer

Breast Cancer

Primary: Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients. — 91; 90…

Imperial College London Results Jun 2020 8.1% serious AE View details

Phase 3 N=644 Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

Crohn's Disease

Primary: Percentage of Participants Achieving Clinical Remission at Week 52 — 34.3; 48.0 percentage of participants — p=0.008

Takeda Results Jun 2020 11.8% serious AE View details

Phase 3 N=102 A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622

Hypereosinophilic Syndrome

Primary: Number of Participants With Common (>=3%) Non-serious Adverse Events (AEs) — 34 Participants

GlaxoSmithKline Results Jun 2020 8.8% serious AE View details

Phase 3 N=23 Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage

Abscess

Primary: Number of Participants With Abscess Resolution — 11; 9 Participants

Baylor College of Medicine Results Jun 2020 0.0% serious AE View details

Phase 3 N=617 Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Depressive Disorder, Major

Primary: The Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 457 Count of Participants

Naurex, Inc, an affiliate of Allergan plc Results Jun 2020 4.5% serious AE View details

Phase 3 N=101 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Brain Stem Glioma · Cerebral Astrocytoma · Childhood Cerebellar Anaplastic Astrocytoma

Primary: Maximum Tolerated Dose (MTD) of Vorinostat — 230 mg/sq m

National Cancer Institute (NCI) Results Jun 2020 37.2% serious AE View details

Phase 3 N=363 A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Lung Cancer

Primary: Progression Free Survival Rate (PFSR) at 6 Months — 0.76; 0.79 Proportion of Participants

Bristol-Myers Squibb Results Jun 2020 37.2% serious AE View details